The U.S. Food and Drug Administration (FDA) granted orphan drug status to a broad spectrum antibiotic called iclaprim, developed by Motif Bio, for the treatment of one of the most common lung infections in patients with cystic fibrosis (CF), Staphylococcus aureus. The FDA’s designation could accelerate the availability of iclaprim for CF patients.
Nitric oxide (NO) inhalation can enhance the antibiotic treatment of Pseudomonas aeruginosa biofilm infections in cystic fibrosis (CF) patients, a small proof-of-concept clinical trial demonstrated. Bacterial infections by P. aeruginosa is a major cause of long-term morbidity and mortality in patients with CF. The bacteria can form biofilms, which are structured, antibiotic-tolerant aggregates…
A nitric oxide therapy that AIT Therapeutics‘ is developing to treat respiratory diseases eradicated a drug-resistant bacteria in one cystic fibrosis patient and reduced it in another, according to a Phase 2 clinical trial. The patients received the treatment under the Food and Drug Administration’s compassionate use program, which allows…
AbbVie is awarding three $25,000 scholarships this year to mark the 25th anniversary of its CF Scholarship Program, and is creating a new Blogger’s Choice Award category. AbbVie selected 40 undergraduate and graduate students living with cystic fibrosis (CF) earlier this year to receive $3,000 scholarships for this…
A new study shows that weight gain during the treatment of acute worsening symptoms in patients with cystic fibrosis (CF), called pulmonary exacerbations, could possibly lengthen the period before symptoms worsen again. These results were published in the European Respiratory Journal Open Research, in an article titled, “…
Cystic Fibrosis Canada has launched a free e-learning module that provides a comprehensive overview of cystic fibrosis (CF) to anyone interested. The Sept. 12 announcement coincides with this year’s back-to-school season. The module contains information to help people understand this complex disease. It has an interactive format designed for both professional and…
Anthera Pharmaceuticals has enrolled half the patients it is seeking for a Phase 3 clinical trial of Sollpura (lipromatase) as treatment for a cystic fibrosis-related digestive disorder known as exocrine pancreatic insufficiency, or EPI. The company expects to release the key results of the RESULT trial in late 2017 or early…
GeneFo is offering a free online lecture on Sept. 27 about the therapeutic benefits of humor and laughter as strategies to manage disease symptoms in cystic fibrosis. The webinar will provide practical assistance for patients and caregivers on how to enjoy a good laugh, even when living with such a complex disease. Cystic…
The risk of cystic fibrosis patients with chronic Achromobacter infections dying or having to have a lung transplant is twice as high than in patients who don’t have the bacteria, a study indicates. Researchers published the study, titled “Clinical Outcomes Associated with Achromobacter Species Infection in Patients with…
Cystic Fibrosis Foundation Therapeutics has given Pulmatrix a grant to test the safety of PUR1900 as a treatment for allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis and asthma patients. The grant will allow Pulmatrix to assess the safety of the anti-fungal drug this fall, paving the way for a Phase 1/1B trial in…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.